Beth A Christian, MD

Beth A Christian, MD

Physician

4.9 out of 5

Specialty:Hematology

Gender: female

Academic Title: Professor in the College of Medicine

Research Program: Leukemia and Hematologic Malignancies

  • About Me

    I am a hematologist and oncologist who specializes in treating patients with aggressive and indolent B-cell non-Hodgkin’s and Hodgkin’s lymphoma. I studied biomedical engineering at Tulane University before receiving my medical training at The Ohio State University, and I have been a faculty member since 2009. I am currently a professor in the Division of Hematology and director of the Hematology and Medical Oncology Fellowship Program. Medical education is very important to me, and I am dedicated to teaching and mentoring trainees who will be future leaders in the fight against lymphoma and other cancers. As a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, my research is focused on finding novel therapies for cancer patients by designing and leading clinical trials. I am inspired by the dual focus on both cutting-edge research and quality patient care that I find at OSUCCC – James. It’s what makes The James such a unique place.

  • Clinical Expertise

    • Non-Hodgkin Lymphoma
    • Lymphomas
    • Hodgkin Lymphoma
    • Blood Cancers
  • Research Interests

    • Lymphoma, Non-Hodgkin
    • Hyperkalemia
    • Lymphoma, Follicular
    • Lymphoma, Large B-Cell, Diffuse
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • Neoplasm, Residual
    • Lymphoma, Mantle-Cell
    • Lymphoma
    • Lymphoma, B-Cell
    • Tumor Lysis Syndrome
  • Where I See Patients

  • Education & Training

    Medical School

    • Ohio State University College of Medicine
      370 W 9Th Ave, Columbus, OH

    Fellowship - Hematology & Oncology

    • Ohio State University Wexner Medical Center
      700 Ackerman Rd, Columbus, OH

    Internship - Internal Medicine

    • Ohio State University Wexner Medical Center
      700 Ackerman Rd, Columbus, OH

    Residency - Internal Medicine

    • Ohio State University Wexner Medical Center
      700 Ackerman Rd, Columbus, OH
  • Academic Office & Contact Information

    Academic Office:

    Lincoln Tower 1110G
    1800 Cannon Dr
    Columbus, Ohio 43210

  • Reviews

    Patient Satisfaction Review

    The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

    The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

    4.9 out of 5 overall

    Kept you informed about your condition and treatment
    4.9 / 5
    Amount of time spent with you
    4.9 / 5
    Concern for your questions and issues
    4.9 / 5
    Skill and knowledge
    4.9 / 5
    Overall quality of care
    4.9 / 5

    Patient Comments

    Reviewed on January 12, 2025

    Dr Beth Christian and Samantha have always strived to make sure I feel like I'm the only person they are working with. Their dedication is unfailing.

    Reviewed on December 18, 2024

    Excellent.

    Reviewed on November 29, 2024

    Care from Dr. Christian and her staff is excellent. She is proactive in treatment, discusses all options. I could not ask for a better doctor.

    Reviewed on November 24, 2024

    Dr. Christians team is wonderful to me. I feel very comfortable with them.

    Reviewed on November 22, 2024

    Dr. Christian is wonderful. She treats me like a person and remembers little personal details of my life and talk to me like a friend. I don't know how she remembers those details about people. She's a true asset to OSU and to those that she cares for.

    Reviewed on November 14, 2024

    Excellent care couldn't ask for any better and I love Dr. Christian. She actually listens to you really listens. She's the best. So caring and understanding and truthful!

    Reviewed on November 3, 2024

    Dr. Christian and her staff are very courteous, super caring and quickly responsive. Dr. Christian gives freely of her time and expertise. She truly takes care of the "whole person." We greatly appreciate the personal phone calls and prompt return of email messages and calls by her 2 NPs.

    Reviewed on October 30, 2024

    Recommended by a doctor that left, and I'm going to be very happy and comfortable with her.

    Reviewed on October 24, 2024

    We had a wonderful nurse who checked me in and she was great! Then we saw Dr. Beth Christian's Fellow, who was very educational, kind, informative, and extremely helpful. My appointment with Dr Christian was amazing. We (myself, my husband, and my son) learned so much that we had not yet been informed about. Dr Christian spent so much time with us, explaining so patiently, and kindly about my cancer and my treatment options. She was amazing, kind, caring, compassionate, while being honest, straightforward, and offering lots of hope. Everything I needed and more!

    Reviewed on August 27, 2024

    The staff was very informative and listened to my concerns and tried to address them that same day. Very friendly and open on the situations I was dealing with.

    Reviewed on August 20, 2024

    Absolutely beyond my expectations on all levels! Thankful.

    Reviewed on August 7, 2024

    Todo eselente

    Reviewed on August 5, 2024

    Dr. Christian and her staff are share test results in a gentle, honest way. Although I get some of the results on MyChart before the appointment, I don't read them because I can't interpret them like they do.

    Reviewed on July 3, 2024

    Dr. Christian met with me this time. She is a lovely, knowledgeable doctor who just naturally fosters faith in her treatment. I feel blessed to have been referred to her care.

    Reviewed on July 2, 2024

    EVERYONE throughout the onset of my lymphoma, through the follow ups post surgery and post chemo have been incredible. They are a blessing and I owe my life to them.

    Reviewed on June 21, 2024

    Life saving experience, cancer free

    Reviewed on June 1, 2024

    Dr. Christian & her staff are all awesome.

    Reviewed on May 30, 2024

    Dr.Christian is a excellent doctor who I have full trust in. I drive 11 hrs to see her because I trust the care & all the information about my condition.

    Reviewed on May 21, 2024

    I always feel relaxed and in a Good mood.Accredited to the whole Staff

    Reviewed on May 7, 2024

    She goes above abd beyond and truly cares and takes the time you need

    Reviewed on May 6, 2024

    Dr. Christian is awesome.

    Reviewed on May 5, 2024

    I wish I had an option of 10 Dr Christian and her team are excellent!

    Reviewed on May 5, 2024

    Amazing experience!

    Reviewed on April 21, 2024

    Dr. Christian is compassionate and patient and extremely knowledgeable. It's a privilege to be her patient.

    Reviewed on April 18, 2024

    Dr. Christian is always ready to listen. She takes the time to answer my questions no matter how busy she is -- and she must be very busy! She carefully listens and responds to concerns. So does her staff -- Shelley and Sam are always very responsive and helpful.

    Reviewed on March 26, 2024

    Love Shelly, Dr. Christian and the team! I feel lucky to be in their care.

    Reviewed on February 27, 2024

    Dr. Christian and her staff are the BEST!!!!

    Reviewed on February 11, 2024

    I literally cannot come up with any negative. Thoughts in regards to my treatment, or service, doctor, nurses, or staff.

    Reviewed on January 23, 2024

    Dr. Christian and Sam are amazing. They have a legitimate stake in their patients and families.

    Reviewed on January 16, 2024

    Great team!

    Reviewed on December 29, 2023

    She always makes me feel like she has all the time in the world for me!! And I know that is not true

    Reviewed on December 26, 2023

    Dr. Christian and her staff are phenomenal.

    Reviewed on December 24, 2023

    Wonderful team

    Reviewed on December 12, 2023

    My doctor and all staff are congenial and willing to make the visit comfortable.

    Reviewed on November 27, 2023

    Love Dr. Christian and staff

    Reviewed on October 22, 2023

    I love Dr Christian.She really listened to me! And gave me the best options with what was important to me. She was my second opinion, and thank God that I got her! Would not go anywhere else for treatment. She is such a Blessing!

    Reviewed on October 18, 2023

    Dr. Beth Christian and her Nurse PRACTITIONER(s)always seems upbeat, knowledgeable and caring.

    Reviewed on August 8, 2023

    In all the visits I have had with Dr. Christian over a five-year period, she has listened patiently, compassionately, and attentively to all of what I have wanted to say. My visits are never rushed. She discusses my concerns with me thoroughly and seeks my input before suggesting next steps in my care.

    Reviewed on July 13, 2023

    Dr. Beth Christian is the best of the best. She has been ou9tstanding throughout my course of care, from diagnosis through treatment and now in remission care.

    Reviewed on July 6, 2023

    Very good experience

    Reviewed on June 24, 2023

    I'm so impressed with dr Christian and consider myself lucky that I'm under her care

  • Publications

    October 18, 2024

    Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.

    Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzmán A, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla N

    Blood Cancer J

    September 22, 2024

    Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.

    Strati P, Champion R, Coleman M, Smith SM, Venugopal P, Martin P, Wood A, Miller K, Christian B

    Br J Haematol

    August 30, 2024

    Evaluation of prognostic factors for high-risk classical Hodgkin lymphoma undergoing autologous transplantation.

    Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, Karmali R, Bello C, Chavez JC, Kothari SK, Hernandez-Ilizaliturri FJ, Svoboda J, Lansigan F, Glenn MJ, Cohen JB, Sorge C, Christian B, Herrera AF, Hamadani M, Costa LJ, Xavier AC

    Blood Adv

    May 1, 2024

    Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.

    Annunzio K, Bhatta S, Hanel W, Zhao Q, Owen M, Rosen H, Voorhees TJ, Bond DA, Sawalha Y, Sigmund AM, Alinari L, Baiocchi RA, Maddocks KJ, Jones D, Christian B, Epperla N

    Hematol Oncol

    March 23, 2024

    Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.

    Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, Wu D, Chan WK, Bezerra ED, Epperla N, Voorhees TJ, Brammer JE, Kittai AS, Bond DA, Sawalha Y, Sigmund AM, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks KJ, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski SM, Li Z, Huang X, Yang Y

    Blood Adv

    December 13, 2023

    Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in USA: A Real World Analysis.

    Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, Olszewski AJ, Bartlett NL

    Blood Adv

    November 1, 2023

    NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

    Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H

    J Natl Compr Canc Netw

    October 17, 2023

    A cancer disparities curriculum in a hematology/oncology fellowship program.

    Husain M, Faisal MS, Quiroga D, Sigmund AM, Otterson G, Walker A, Obeng-Gyasi S, Christian B

    BMC Med Educ

    October 4, 2023

    Impact of circulating lymphoma cells at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.

    Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzmán A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Ramakrishnan Geethakumari P, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla N

    Blood Adv

    May 8, 2023

    Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.

    Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, Anampa-Guzmán A, Oh TS, Reaves H, Tavakkoli M, Lindsey K, Greenwell IB, Hansinger E, Thomas C, Chowdhury SM, Annunzio K, Christian B, Barta SK, Geethakumari PR, Bartlett NL, Herrera AF, Grover NS, Olszewski AJ

    J Hematol Oncol

    May 2, 2023

    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.

    Zinzani PLL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto LM, Martin Garcia-Sancho A, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P

    Blood

    February 24, 2023

    A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.

    Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L

    Cancers (Basel)

    October 26, 2022

    Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy.

    Annunzio K, Cackovic M, Bond DA, Sawalha Y, Voorhees TJ, Hanel W, Alinari L, Baiocchi RA, Reneau JC, Brammer JE, Maddocks K, Christian B, Epperla N

    Blood Adv

    October 21, 2022

    Postibrutinib relapse outcomes for patients with marginal zone lymphoma.

    Epperla N, Zhao Q, Mullick Chowdhury S, Shea L, Moyo T, Reddy N, Sheets JW, Weiner DM, Ramakrishnan Geethakumari P, Kandarpa M, Jordan Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen LD, Tan XC, Lindsey KG, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova ER, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G

    Blood Adv

    July 16, 2022

    Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.

    Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G

    J Hematol Oncol

    January 1, 2022

    Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study.

    Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha Y

    Ther Adv Hematol

    November 17, 2021

    Feasibility of High-dose Methotrexate Administered on Day 1 of (R)CHOP in aggressive non-Hodgkin Lymphomas.

    Fleming MK, Huang Y, Dotson EK, Bond DA, Reneau JC, Epperla N, Alinari L, Brammer JE, Christian B, Baiocchi RA, Maddocks K, Sawalha Y

    Blood Adv

    November 1, 2021

    NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.

    Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H

    J Natl Compr Canc Netw

    April 27, 2021

    Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.

    Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman JP

    Leukemia

    April 7, 2021

    Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.

    Advani R, Moskowitz AJ, Bartlett NL, Vose J, Ramchandren R, Feldman T, LaCasce AS, Christian B, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF

    Blood

    October 1, 2020

    Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.

    Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, Diefenbach CS, Feldman TA, Ansell SM

    Lancet Haematol

  • Consulting and Related Relationships

    At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Christian has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

    • AstraZeneca
    • Ipsen